Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMT-562 in Advanced Solid Tumors
NCT06199908Phase 1Recruiting
- Sponsor
- Multitude Therapeutics
- Start
- May 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AMT-562 in solid tumor (advanced stage), sponsored by Multitude Therapeutics. Primary endpoints: Dose-Limiting Toxicities at 24 month, Adverse Events at 24 month and 1 more. Started May 2024; status: recruiting.
02
Drugs
AMT-562
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06199908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06199908.